Aptamer-Based Free EGFR Detection for Cancer Resistance Monitoring
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for monitoring cancer resistance to therapeutic molecules targeting the EGFR, such as cetuximab and panitumumab, are inadequate in determining the amount of free EGFR, which is crucial for optimizing treatment efficacy.
Innovation Solution
Development of aptamers that specifically bind to free EGFR, allowing for the determination of free EGFR levels in patient samples, and optimization of therapeutic dosages based on the proportion of free to total EGFR.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If therapeutic antibodies (cetuximab or panitumumab) are used to treat cancer by binding EGFR, then cancer treatment efficacy is improved, but the ability to monitor free EGFR levels and detect resistance becomes inadequate
Solution Approach 1:
The patent uses an aptamer as an intermediary binding agent that specifically binds to free EGFR. This aptamer serves as a mediator between the therapeutic antibody and the detection system, allowing precise measurement of free EGFR levels without interfering with the therapeutic antibody's action on cancer cells.
Solution Approach 2:
The patent extracts the measurement function from the therapeutic monitoring system by introducing a separate aptamer-based detection method. This allows the therapeutic antibody to continue its cancer-fighting function while the aptamer independently performs the measurement of free EGFR levels, resolving the conflict between treatment and monitoring.
2Duration of action of stationary object
If current monitoring methods are used for cancer resistance, then treatment continuation is maintained, but accurate detection of free EGFR and resistance development cannot be determined
Solution Approach 1:
The patent replaces conventional antibody-based detection methods with aptamer-based detection. Aptamers offer superior binding characteristics and can be engineered for enhanced stability and detection properties, making the measurement of free EGFR levels more accurate and reliable while allowing treatment to continue uninterrupted.
3Reliability
If therapeutic dosages are optimized based on free EGFR proportion, then treatment efficacy is improved, but the complexity of monitoring and determining free to total EGFR ratio increases
Solution Approach 1:
The aptamer system is designed to perform multiple functions: it specifically binds free EGFR, enables quantification through detection labels, and provides the basis for calculating the free to total EGFR ratio. This multi-functional design streamlines the monitoring process while maintaining the ability to optimize dosages based on accurate measurements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables accurate monitoring of cancer resistance and optimization of therapeutic efficacy by quantifying free EGFR levels, potentially leading to improved treatment outcomes for patients.
Implementation Method 1
contacting a sample with an aptamer that specifically binds to free EGFR under conditions that allow binding of the aptamer to the free EGFR in the sample to form an aptamer-EGFR complex
Data Source
AI summary
The present invention provides aptamers that specifically bind to the EGF receptor in a sample, and diagnostic and analytical methods using those aptamers. In some embodiments, the aptamers include a 3′ cap. In some embodiments, the 3′ cap is an inverted deoxythymidine. In some embodiments the aptamers include a spacer and at least one moiety selected from the group consisting of binding pair member and a detectable label, wherein the spacer is attached to the 5′-end of the aptamer and the moiety is attached the 5′ end of the spacer. In some embodiments the spacer is hexaethylene glycol. In some embodiments, the binding pair member biotin. In some embodiments the detectable label is a fluorophore.